Follow us on:

Eden Research doorways open as Mevalone approved in 17 US states and Cedroz in 8 (VIDEO)

Eden Research Plc (LON:EDEN) CEO Sean Smith joins DirectorsTalk Interviews to discuss regulatory approval for its formulated products Mevalone® and Cedroz™.

Sean explains why they need ‘state approval’ when it was already announced that they had ‘national approval’, with California being one of the most important states the impact not yet having approval has on the business, when to expect approval and what else the company is expecting in terms of regulatory approvals.

EDEN RESEARCH IS FOCUSED ON SUSTAINABLE BIOPESTICIDES AND PLASTIC-FREE ENCAPSULATION TECHNOLOGY FOR USE IN GLOBAL CROP PROTECTION, ANIMAL HEALTH AND CONSUMER PRODUCTS INDUSTRIES.

Find more news, interviews, share price & company profile here for:Eden Research plc

Share this interview

Other Interviews

Eden Research looking forward to strong demand from important markets (VIDEO) September 27, 2022
Eden Research seeing strong demand through the first half of the year (VIDEO) August 24, 2022

More News

Eden Research doorways open as Mevalone approved in 17 US states and Cedroz in 8 (VIDEO) March 24, 2023
Eden Research Plc granted numerous US state regulatory approvals March 23, 2023
Eden Research flagship biofungicide, Mevalone authorisation for domestic use January 30, 2023
Best green shares UK – Active Energy Group, Saietta Group, Tirupati Graphite, Cadence Minerals, Eden Research plc January 13, 2023
Eden Research CEO Sean Smith “2022 has been a productive year” January 10, 2023
Eden Research signs distribution agreement with with Corteva France December 15, 2022
Eden Research receives certification for Mevalone and Cedroz in Greece November 30, 2022
Green news: AMTE Power, Eden Research, Dialight plc, Ferro-Alloy Resources, Tirupati Graphite, CyanConnode October 24, 2022
Eden Research to capitalise on the significant and growing market opportunity available September 30, 2022
Eden Research looking forward to strong demand from important markets (VIDEO) September 27, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.